Take Ltd
Incorporated in 2000, TAKE Solutions Ltd is in the business of Life Sciences and Support Services[1]
- Market Cap ₹ 351 Cr.
- Current Price ₹ 23.8
- High / Low ₹ 50.1 / 9.85
- Stock P/E 60.2
- Book Value ₹ 1.93
- Dividend Yield 0.00 %
- ROCE 11.6 %
- ROE 9.99 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 12.3 times its book value
- Tax rate seems low
- Company has a low return on equity of -46.6% over last 3 years.
- Earnings include an other income of Rs.7.98 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.89 | 23.57 | 18.84 | 2.44 | 21.96 | 2.47 | 10.72 | 18.00 | 56.23 | 5.42 | 0.90 | 0.00 | 11.93 | |
| 24.45 | 18.36 | 22.44 | 18.64 | 35.83 | 19.38 | 17.59 | 31.35 | 53.37 | 14.94 | 2.95 | 3.45 | 13.75 | |
| Operating Profit | 1.44 | 5.21 | -3.60 | -16.20 | -13.87 | -16.91 | -6.87 | -13.35 | 2.86 | -9.52 | -2.05 | -3.45 | -1.82 |
| OPM % | 5.56% | 22.10% | -19.11% | -663.93% | -63.16% | -684.62% | -64.09% | -74.17% | 5.09% | -175.65% | -227.78% | -15.26% | |
| 12.80 | 15.64 | 22.05 | 32.81 | 34.35 | 26.08 | 15.32 | -459.92 | 3.63 | -192.27 | -66.89 | 6.63 | 7.98 | |
| Interest | 0.11 | 0.40 | 3.08 | 1.07 | 0.17 | 0.49 | 0.36 | 0.30 | 0.68 | 0.74 | 0.75 | 0.29 | 0.15 |
| Depreciation | 0.74 | 0.19 | 0.80 | 0.80 | 0.80 | 1.74 | 1.57 | 1.23 | 1.11 | 0.72 | 0.05 | 0.01 | 0.00 |
| Profit before tax | 13.39 | 20.26 | 14.57 | 14.74 | 19.51 | 6.94 | 6.52 | -474.80 | 4.70 | -203.25 | -69.74 | 2.88 | 6.01 |
| Tax % | 15.46% | 10.02% | 1.10% | -3.39% | 10.81% | -11.38% | -19.63% | 0.50% | 8.72% | 1.97% | 0.00% | 5.56% | |
| 11.32 | 18.23 | 14.42 | 15.25 | 17.40 | 7.74 | 7.79 | -477.17 | 4.29 | -207.25 | -69.74 | 2.72 | 5.85 | |
| EPS in Rs | 0.92 | 1.49 | 1.08 | 1.03 | 1.18 | 0.52 | 0.53 | -32.26 | 0.29 | -14.01 | -4.71 | 0.18 | 0.41 |
| Dividend Payout % | 106.01% | 65.88% | 92.37% | 155.17% | 85.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -100% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -15% |
| 5 Years: | 20% |
| 3 Years: | -32% |
| TTM: | -30% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -18% |
| 5 Years: | -16% |
| 3 Years: | 9% |
| 1 Year: | 149% |
| Return on Equity | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | -53% |
| 3 Years: | -47% |
| Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.00 | 12.01 | 13.32 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 |
| Reserves | 304.24 | 306.70 | 504.69 | 754.74 | 747.66 | 751.03 | 760.28 | 283.65 | 287.98 | 80.62 | 10.97 | 13.69 |
| 0.00 | 72.77 | 0.00 | 0.00 | 0.00 | 3.85 | 0.00 | 2.39 | 1.82 | 0.00 | 0.00 | 0.00 | |
| 8.80 | 22.35 | 16.03 | 7.15 | 11.81 | 6.62 | 11.20 | 10.94 | 14.11 | 23.77 | 5.91 | 1.57 | |
| Total Liabilities | 325.04 | 413.83 | 534.04 | 776.68 | 774.26 | 776.29 | 786.27 | 311.77 | 318.70 | 119.18 | 31.67 | 30.05 |
| 0.63 | 0.48 | 4.60 | 3.86 | 3.07 | 5.97 | 4.43 | 3.24 | 2.12 | 0.11 | 0.01 | 0.00 | |
| CWIP | 0.00 | 2.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 234.38 | 330.39 | 359.92 | 413.87 | 511.72 | 517.32 | 516.78 | 154.68 | 242.56 | 101.87 | 0.00 | 0.25 |
| 90.03 | 80.80 | 169.52 | 358.95 | 259.47 | 253.00 | 265.06 | 153.85 | 74.02 | 17.20 | 31.66 | 29.80 | |
| Total Assets | 325.04 | 413.83 | 534.04 | 776.68 | 774.26 | 776.29 | 786.27 | 311.77 | 318.70 | 119.18 | 31.67 | 30.05 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.55 | -10.77 | -32.96 | -24.02 | 12.91 | -14.91 | -2.66 | 32.58 | 26.89 | -4.48 | -19.51 | -0.62 | |
| 55.39 | -91.88 | -23.57 | -87.92 | -111.90 | 21.79 | 13.42 | -40.19 | -22.37 | -1.02 | 22.21 | -2.00 | |
| -11.96 | 60.53 | 57.88 | 239.40 | -28.45 | -8.26 | -0.25 | -1.11 | -0.84 | -0.23 | -0.04 | -0.29 | |
| Net Cash Flow | 40.87 | -42.12 | 1.36 | 127.46 | -127.44 | -1.38 | 10.51 | -8.72 | 3.69 | -5.73 | 2.66 | -2.91 |
| Free Cash Flow | -2.36 | -12.96 | -36.01 | -24.08 | 12.90 | -14.91 | -2.69 | 32.54 | 26.89 | -4.49 | -19.51 | -0.62 |
| CFO/OP | -12% | -159% | 785% | 129% | -101% | 81% | 37% | -245% | 1,095% | 40% | 966% | 13% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 42.58 | 57.76 | 61.61 | 136.13 | 106.87 | 1,034.41 | 80.69 | 87.19 | 0.00 | 0.00 | 0.00 | |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 42.58 | 57.76 | 61.61 | 136.13 | 106.87 | 1,034.41 | 80.69 | 87.19 | 0.00 | 0.00 | 0.00 | |
| Working Capital Days | 394.32 | -731.70 | 1,958.48 | 26,942.68 | 3,456.03 | 33,992.29 | 7,838.99 | 1,844.47 | 241.86 | -1,163.02 | 5,406.06 | |
| ROCE % | 4.24% | 4.40% | 3.95% | 2.44% | 2.46% | 0.97% | -0.90% | 0.50% | 3.57% | -4.68% | 17.96% | 11.65% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences Revenue Share % |
|
|||||||||
| Total Employee Headcount count |
||||||||||
| Clinical Bed Capacity count |
||||||||||
| USA Revenue Share % |
||||||||||
| Order Book USD million |
||||||||||
| New Client Logos Added count |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Advertisement of the Unaudited Financial Results for the quarter ended June 30, 2026.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Q1 FY27 results: revenue ₹30.37 Cr, net profit ₹1.06 Cr; announces longevity and nutraceuticals entry.
-
Board Meeting Outcome for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026
- Board approved Q1 FY27 results; consolidated revenue ₹30.37 crore, net profit ₹1.06 crore.
-
Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2026.
- TAKE Limited approved Q1 FY27 results; consolidated revenue ₹30.37 crore, net profit ₹1.06 crore.
-
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.
- Board meeting on August 11, 2026 to approve Q1 FY27 results; trading window reopens after results.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Dec 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Mar 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Nov 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Dec 2016TranscriptPPT
-
Oct 2016TranscriptPPT
-
Feb 2016TranscriptAI SummaryPPT
Business Overview:[1]
Singapore-based TAKE Solutions Pte Limited holds a 52.90% stake in TSL, serving as the holding company. TSL specializes in Life Sciences and Supply Chain Management, providing comprehensive services in clinical development and specific offerings in supply chain. The company is involved in clinical trials, generics support, including bio-availability & bioequivalent studies, regulatory filing, and pharmacovigilance.